+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression



Stromelysin 3: an independent prognostic factor for relapse-free survival in node-positive breast cancer and demonstration of novel breast carcinoma cell expression



American Journal of Pathology 152(3): 721-728



Stromelysin 3 (ST3) is a matrix metalloproteinase implicated in mammary carcinoma progression. To date, localization of ST3 expression in breast cancer by in situ hybridization and immunocytochemistry has shown that the expression of the enzyme is limited to only the stromal fibroblasts surrounding the cancer cells. We have immunostained a large group of ductal carcinoma in situ and invasive breast carcinomas using a monoclonal antibody (5ST-4A9) raised against the hemopexin-like domain of human ST3. We show that invasive lobular carcinomas express significantly less ST3 than invasive ductal carcinomas (IDCS) (P = 0.002). We also show, for the first time, that certain breast carcinoma cells that have undergone a degree of epithelial-to-mesenchymal transition, the so-called metaplastic carcinomas, can express ST3 mRNA and protein, which may in part explain the increased metastatic propensity seen in a number of these tumors. in addition, patients with EDC who had moderate to strong ST3 levels had significantly shorter disease-free survival than those with negative or weak ST3 levels (P = 0.02). Furthermore, in node-positive IDC patients, multivariate analysis revealed that ST3 level was a strong, independent prognostic parameter for disease-free survival (P = 0.005).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009463320

Download citation: RISBibTeXText

PMID: 9502414


Related references

Stromelysin-3 expression An independent prognostic marker in node positive breast carcinoma. Journal of Pathology 184(SUPPL ): 23A, 1998

Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene 21(55): 8506-8509, 5 December, 2002

Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clinical Cancer Research 8(4): 1054-1060, 2002

Gene expression of PMP22 is an independent prognostic factor for disease-free and overall survival in breast cancer patients. Bmc Cancer 10: 682, 2011

High Expression of Three-Gene Signature Improves Prediction of Relapse-Free Survival in Estrogen Receptor-Positive and Node-Positive Breast Tumors. Biomarker Insights 10: 103-112, 2015

The lymph node ratio as an independent prognostic factor for node-positive triple-negative breast cancer. Oncotarget 8(27): 44870-44880, 2017

The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality. Journal of B.U.On. 20(3): 737-745, 2015

pS2 is an independent prognostic factor for post-relapse survival in primary breast cancer. Anticancer Research 18(1b): 577-582, 1998

Mammaglobin is associated with low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent prognostic value for relapse-free survival time. Journal of Clinical Oncology 22(4): 691-698, 2004

Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. European Journal of Cancer 40(1): 33-42, 2003

Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clinical Cancer Research 12(22): 6696-6701, 2006

Pepsinogen C, an independent favorable prognostic factor in node-positive breast cancer patients. Proceedings of the American Association for Cancer Research Annual Meeting 40: 205, 1999

Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: review of a series of 271 patients with stage I and II breast cancer. Cancer Radiotherapie 9(8): 575-586, 2005

Combined flow cytometry determination of S-phase fraction and DNA ploidy is an independent prognostic factor in node-negative invasive breast carcinoma: analysis of a series of 271 patients with stage I and II breast cancer. Breast Cancer Research and Treatment 91(1): 61-71, 2005

Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer. Indian Journal of Surgical Oncology 1(1): 68-75, 2010